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Human amniotic membrane-derived mesenchymal stem 
cells  (hAM-MSCs)  are  capable  of  differentiating  into 
several lineages and possess immunomodulatory properties. 
In this study, we investigated the soluble factor-mediated 
immunomodulatory effects of hAM-MSCs. Mitogen-induced 
peripheral blood mononuclear cell (PBMC) proliferation 
was suppressed by hAM-MSCs in a dose-dependent manner 
as  well  as  hAM-MSC  culture  supernatant.  Moreover, 
interferon-gamma  and  interleukin  (IL)-17  production 
significantly decreased from PBMC, whereas IL-10 from 
PBMCs  and  transforming  growth  factor  beta  (TGF-β) 
production  from  hAM-MSCs  significantly  increased  in 
co-cultures  of  hAM-MSCs  and  PBMCs.  Production  of 
several MSC factors, including hepatocyte growth factor 
(HGF), TGF-β, prostaglandin E2 (PGE2), and indoleamine 
2, 3 dioxygenase (IDO), increased significantly in hAM-MSCs  
co-cultured with PBMCs. These results indicate that the 
immunomodulatory effects of hAM-MSCs may be associated 
with  soluble  factors  (TGF-β,  H G F ,  P G E 2 ,  a n d  I D O ) ,  
suggesting that hAM-MSCs may have potential clinical use 
in regenerative medicine.
Keywords: amniotic membrane, IL-10, immune modulation, 
mesenchymal stem cells, TGF-β
Introduction
Mesenchymal stem cells (MSCs) are multipotent non- 
hematopoietic progenitor cells which can differentiate into 
several mesenchymal lineages [4,10,18]. Another important 
characteristic of these cells is associated with their 
immunomodulatory properties. MSCs can suppress 
several types of immune cells including T [7,13], B [6], NK 
[23], and dendritic cells [29]. Furthermore, MSCs have 
been reported to ameliorate experimental murine auto-
immune encephalomyelitis in a model of multiple sclerosis 
[28], prolong the survival of baboon skin in an allo-
transplation model [2], and control lethal graft vs. host 
complications [14]. These attributes have generated 
interest in the clinical use of MSCs in regenerative 
medicine [18].
Because bone marrow derived MSCs (BM-MSCs) 
represent a rare population (below 0.1% of nucleated cells) 
of adult cells, MSCs from alternative sources such as cord 
blood and adipose tissue are important. The placenta and 
its membranes, which are readily available and not 
associated with any substantial ethical issues, have received 
particular attention as a source of stem cells possessing 
multi- and pluripotent differentiation abilities. Furthermore, 
amniotic membrane-derived MSCs (AM-MSCs) inhibit 
allogeneic immune responses similar to BM-MSCs [4,15]. 
The major mechanism underlying immune-modulation by 
MSCs involves soluble factors such as transforming 
growth factor beta (TGF-β) [7], hepatocyte growth factor 
(HGF) [7], prostaglandin E2 (PGE2) [1] and indoleamine 
2, 3 dioxygenase (IDO) [19]. In addition, cell-cell contact 
is also a possible factor that influences immune-modulation. 
However, its relevance to MSC function is not well 
understood.
  In this study, we isolated human amniotic membrane- 
derived MSCs (hAM-MSCs) and investigated their 
characteristics and immunomodulatory effects. This was 
done to determine which factors are expressed and how 24    Jung Won Kang et al.
expression of these factors is induced when hAM-MSCs 
are co-cultured with host immune cells. In this way, the 
possible use of hAM-MSCs for therapeutic use could be 
assessed.
Materials and Methods
Isolation of hAM-MSCs
hAM-MSCs in the third passage from different five 
donors were provided by RNL Bio, Korea. Briefly, human 
placentas were obtained after vaginal deliveries or 
caesarean section births from healthy women after 
obtaining informed consent. All human tissues were 
obtained with the approval of the Korea University 
Medical Center Institutional Review Board (Korea). The 
amnion were mechanically peeled from the placenta and 
washed with sterile saline several times to remove excess 
blood. Approximately 2.5 g of amnion tissues were cut into 
small pieces with scissors and digested with protease 
enzyme, collagenase type I (Gibco, USA), in shaking 
incubator at 37
oC for 1 h The digested tissues were filtered 
through 100 μm cell strainers (Falcon, USA) and centrifuged 
at 850 × g for 4 min. The pellet was resuspended in alpha- 
minimum essential medium (MEM; Gibco, USA) based 
medium containing 10% fetal bovine serum (FBS; PAA, 
Australia) and seeded into T75 flasks (Nunc, Denmark). 
The cultures were maintained at 37
oC in a humidified 
atmosphere with 5% CO2. Cell attachment was evaluated 
under a microscope 4 days after incubation and non- 
adherent cells were discarded by changing the medium. 
The cells were subcultured and expanded when the cells 
reached 90% confluence. The cells were used for the 
experiments at passage 3. The procedure for hAM-MSC 
preparation was performed under good manufacturing 
practice conditions [9].
Flow cytometry analysis
The immunophenotype of the AM-MSCs was analyzed 
by flow cytometry (FACSCalibur; BD Biosciences, USA) 
using CellQuest software (BD Biosciences, USA). Anti-
bodies against human antigens CD29 (BD555443), CD31 
(BD555445), CD34 (BD555822), CD44 (BD555478), 
CD45 (BD555482), CD73 (BD550257), CD90 (BD555596), 
histocompatibility locus antigen (HLA)-ABC (BD555552), 
and HLA-DR (BD555811) were purchased from BD 
Pharmingen (USA). Antibody against human antigen 
CD105 (FAB10971P) was purchased from R&D Systems 
(USA). Trypsinized cell were suspended in 5% bovine 
serum albumin and stained with specific antibody for 2 h. 
After stainining, cells were analyzed flow cytometry.
In vitro differentiation of hAM-MSCs
Osteogenic induction: At 50% confluence, hAM-MSCs 
were cultured for 14 days in NH Osteodiff Medium 
(Miltenyi Biotec, Germany) with 90% of the medium 
replaced every 3 days. Cells were stained with Alizarin red 
S (Sigma-Aldrich, USA). Cells were fixed in 70% ethanol, 
stained with 40 mM Alizarin Red S solution (pH 4.2) for 1 
h. After staining, cells were washed with PBS and observed 
a microscope (Axiovert 300; Carl Zeiss, Germany).
Adipogenic induction: At 80% confluence, AM-MSCs 
were cultured for 21 days in adipogenic induction medium 
contained low glucose-Dulbecco’s modified Eagle medium 
(DMEM) with 10% FBS, 200 μM indomethacin (Sigma- 
Aldrich, USA), 1 μg/mL insulin (Sigma-Aldrich, USA), 1 
mM dexamethasone (Sigma-Aldrich, USA), 0.5 mM 
isobutylmethylxanthine (Sigma-Aldrich, USA), 100 U/mL 
penicillin (Gibco, USA), 100 mg/mL streptomycin (Gibco, 
USA), and 0.25 mg/mL amphotericin B (Gibco, USA). 
The medium was replaced with adipocyte induction 
medium or control (stromal) medium, alpha- MEM (Gibco, 
USA)-based medium containing 5% FBS (PAA, Australia) 
with every 3 days. After cells were differentiated into 
adipocytes completely for 2 weeks, cells were fixed in 10% 
formalin and then stained with oil red O solution [40% H2O 
and 60% oil red O stock solution composed of 0.5% oil red 
O (Sigma-Aldrich, USA) in isopropanol (Sigma-Aldrich, 
USA)] for 1 h. After staining, cells were washed with 
distilled water and observed by a microscope (Axiovert 
300; Carl Zeiss, Germany).
Chondrogenic induction: hAM-MSCs (5 × 10
5 cells) 
cultured in alpha-MEM (Gibco, USA)-based medium 
containing 5% FBS (PAA, Australia) were centrifuged at 
500 × g for 5 min. The cells were then resuspended in 0.5 
mL of commercialized NH chondrogenic medium (Miltenyi 
Biotec, Germany) containing dexamethasone, ascorbate, 
insulin-transferrin-selenium, penicillin, sodium pyruvate, 
praline, L-glutamine and TGF-β. The cells were centri-
fuged again at 500 × g for 5 min to form pellets. The pellets 
were cultured in polypropylene tubes for 14 days with 50% 
of the chondrogenic induction medium being replaced 
every 3 to 4 days. After cells were differentiated into 
chondrocytes completely for 3 weeks, cellswere fixed in 
10% formalin, stained with 1% toluidine blue for 15 min 
and then washed with distilled water and observed by a 
microscope (Axiovert 300; Carl Zeiss, Germany).
Peripheral blood mononuclear cells isolation
Peripheral blood mononuclear cells (PBMCs) were 
obtained from healthy volunteers. Briefly, peripheral blood 
sample was diluted with an equal volume of phosphate 
buffered saline, layered onto a Histopaque (specific 
gravity 1.077; Sigma-Aldrich, USA) and centrifuged at 
600 × g for 20 min. PBMCs were collected from the 
interphase and washed twice with PBS. Cell viability was 
analyzed by trypan blue exclusion.Immune-modulation by hAM-MSC    25
Cell proliferation test
hAM-MSCs (1 × 10
3 ∼ 5 × 10
4) irradiated with Cs
137 
(3,000 rad) using GC 3000 Elan (MDS Nordion, Canada) 
were seeded onto 96-well flat bottom plates (Costar, USA). 
PBMCs (1 × 10
5/100  μL) were added to the layer of 
hAM-MSCs and then cultured with concanavalin A 
(ConA, 5 μg/mL; Sigma-Aldrich, USA) for 72 h. For some 
experiments, PBMCs (1 × 10
5 cells/100 μL) were seeded in 
triplicate in 96-well round-bottom plates (Costar, USA) in 
the presence of supernatant obtained from hAM-MSCs (1 
× 10
5 cells) cultured in 6-well plates (Costar, USA) for 72 
h. Leukocyte proliferation was evaluated using a cell 
proliferation BrdU ELISA kit (Roche Diagnostics, 
Germany) according to the manufacturer’s instructions. 
The stimulation index value (mean optical density values 
of mitogen-stimulated cultures/mean optical density 
values of no mitogen-stimulated cultures) was calculated 
for each treatment.
Measurement of cytokine and PGE2 production
hAM-MSCs (1 × 10
5 cells) were seeded in 24-well plates 
(Costar, USA). PBMCs (1 × 10
6 cells) were added onto the 
MSC layer and cultured with ConA (5 μg/mL) for 72 h. 
PBMCs cultured without hAM-MSCs served as a control. 
To determine the amount of interferon-gamma (IFN-γ), 
interleukin (IL)-17, TGF-β, IL-10, and PGE2 in the 
cell-free culture supernatant, commercial ELISA kits 
(Cayman Chemicals, USA) were used according to the 
manufacturer’s instructions.
Determination of IDO enzymatic activity
To determine the amount of IDO enzymatic activity 
catalyzing the degradation of the tryptophan to kynurenine, 
the level of its metabolite, kynurenine, was measured 
spectrophotometrically. Briefly, 50 μL of 30% trichlo-
roacetic acid (Sigma-Aldrich, USA) was added to 100 μL 
of culture supernatant (hAM-MSCs only, co-culture of 
hAM-MSCs and PBMCs and co-culture of hAM-MSCs 
and PBMCs and ConA; 5 μg/mL) , incubated at 50
oC for 30 
min, and then centrifuged at 15,400 × g for 1 min. The 
supernatant (75 μL) was then added to an equal volume of 
Ehrlich’s reagent (100 mg p-dimethylbenzaldehyde and 5 
mL glacial acetic acid; Sigma-Aldrich, USA) in a 96-well 
plate. Optical density was measured at 490 nm using 
microplate reader 680 (Bio-Rad, USA). 
Reverse-transcription  polymerase  chain  reaction 
(RT-PCR)
　After 12 h, PBMCs were removed from hAM-MSC/ 
PBMC co-cultures by gentle PBS washing and total RNA 
was then extracted using Easy-Blue (Intron, Korea) 
according to the manufacturer’s instructions. In some 
experiments, hAM-MSCs were separated from PBMCs by 
a Transwell membrane (0.3 μm pore size; Costar, USA). 
Reverse transcription of 2 μg of total mRNA was 
conducted using a cDNA synthesis kit (Takara, Japan) 
according to manufacturer’s recommendations. PCR 
amplification of cDNA aliquots was then performed in a 
Mastercycler (Eppendorf, Germany) by adding 2.5 mM 
dNTPs, 2.5 U Taq DNA polymerase (Intron, Korea) and 
0.25 μM forward and reverse primers through 30 cycels of 
94
oC for 20 sec, 55
oC for 20 sec, and 72
oC for GAPDH 
and 32 cycels of 94
oC for 20 sec, 55
oC for 20 sec, and 
72
oC for 30 sec for TGF-β, HGF, IDO and cyclooxygenase- 
2 (COX-2). Primer sequences were as follows: GAPDH 
(forward: 5´-aacatcatccctgcttccac-3´, reverse: 5´-gaccacc 
tggtcctcagtgt-3´), TGF-β (forward: 5´-agcaccctacttgagg 
cga-3´, reverse: 5´-actggatcatctccgacagg-3´), HGF (forward: 
5´-atcacccagaatcaggcatc-3´, reverse: 5´-tttccatggcgataaact 
cc-3´), IDO (forward: 5´-ctcagattactacaaccgatc-3´, reverse: 
5´-accaggatctcttgctggat-3´), and COX-2 (forward: 5´-atg 
ctgctaacctaata-3´, reverse: 5´-ctagtgaggctatctttat-3´).
Statistical analysis
Experimental values are presented as the mean ± SD. 
Statistical differences were determined by a t-test using the 
SigmaStat program (ver. 3.0; SigmaStat, USA). p-values < 
0.05 were considered significant.
Results
Characterization and differentiation of hAM-MSCs
The expression of hAM-MSC surface markers was 
determined by flow cytometry. Five samples of hAM- 
MSCs were uniformly positive for CD29 (98.4 ± 1.0%), 
CD44 (99.0 ± 0.7%) CD73 (97.4 ± 18.3%), CD90 (99.8 ± 
0.1%), and CD105 (70.3 ± 13.3%), but negative for CD31 
(0.4 ± 0.6%), CD34 (0.4 ± 0.5%), and CD45 (0.3 ± 0.6%). 
Immunologically, the hAM-MSCs were positive for 
HLA-ABC but negative for HLA-DR (Fig. 1A). Next, we 
investigated the gene expression profile of the hAM-MSCs 
by RT-PCR. As shown in Fig. 1B, the hAM-MSCs con-
stitutively expressed COX-2, HGF, and TGF-β mRNA; 
however, they did not constitutively express IDO and 
IL-10 mRNA. 
The hAM-MSCs underwent differentiation when induced 
with specific factors (Fig. 1C). Osteogenic differentiation 
was confirmed by positive Alizarin red S staining. Almost 
all cells were found to undergo osteogenic differentiation 
shown by red mineralized deposits. Adipogenic differen-
tiation was assessed by positive oil red O staining and 
accumulation of lipid vacuoles within the cells. Chondrogenic 
differentiation was associated with round-shaped inclu-
sions located in lacuna-like structures within the cell 
detected by toluidine blue O staining.26    Jung Won Kang et al.
Fig. 1. Characterization of human amniotic membrane-derived mesenchymal stem cells (hAM-MSCs). (A) Immunophenotyping of 
hAM-MSCs at passage 3 by fluorescence activated cell sorting analysis. Cells were positive for CD29, CD44, CD73, CD90, CD105,
and HLA-ABC but negative for CD31, CD34, CD45, and HLA-DR. (B) Constitutive mRNA expression of angiogenic growth factor
(hepatocyte growth factor [HGF]), cytokines (transforming growth factor beta [TGF-β] and interleukin [IL]-10]), cyclooxygenase-2
(COX-2), and indoleamine 2, 3 dioxygenase (IDO) in steady state hAM-MSCs measured by RT-PCR. GAPDH mRNA was used as an
internal control. M: 100-bp molecular weight ladder. (C) Differentiation of hAM-MSCs. (Ca) Osteogenic differentiation analyzed by 
Alizarin red S staining, (Cb) adipogenic differenction by oil red O staining, and (Cc) chondrogenic differentiation assessed by toluidine
blue O staining. ×100.
Suppression  of  mitogen-induced  proliferation  of 
allogeneic lymphocytes by co-culturing  with hAM- 
MSCs 
To determine whether hAM-MSCs could suppress 
mitogen-induced proliferation of allogeneic lymphocytes, 
PBMCs were stimulated with ConA in the presence of 
hAM-MSCs for 72 h. Allogeneic PBMC proliferation as a 
result of mitogen treatment was inhibited by AM-MSCs 
(Fig. 2; p < 0.05). To evaluate whether the number of 
hAM-MSCs was related to the degree of suppression of 
PBMC proliferation, various amounts of hAM-MSCs were 
co-cultured with PBMCs. A shown in Fig. 2A, hAM-MSCs 
inhibited ConA-induced PBMC proliferation in a dose- 
dependent manner. When hAM-MSCs were incubated 
with PBMCs at ratios of 1 : 2 and 1 : 10, PBMC proliferation 
was successfully abrogated (p < 0.05). However, there was 
no significant difference in proliferation when hAM-MSCs 
were incubated with PBMCs at a ratio of 1 : 100 compared 
to that observed without the addition of hAM-MSCs (p > 
0.05). Supernatant from hAM-MSC cultures was added to 
PBMC cultures stimulated with ConA in order to determine 
whether soluble factors secreted by hAM-MSCs were 
associated with the immunomodulatory effect we observed. 
Leukocyte proliferation in response to mitogenic stimulus 
was blocked by the addition of hAM-MSC culture 
supernatant (Fig. 2B).
Cytokine  profile  of  media  from  co-cultures  of 
hAM-MSCs and PBMCs
To examine the effect of hAM-MSCs on the activity of the Immune-modulation by hAM-MSC    27
Fig. 2. Suppressive effects of hAM-MSCs on the proliferation of peripheral blood mononuclear cell (PBMC): (A) PBMCs (1 × 10
5
cells) cultured with ConA (5 μg/mL) in the presence or absence of irradiated hAM-MSCs (1 × 10
3 ∼ 5 × 10
4 cells) for 3 days. (B) 
PBMCs (1 × 10
5 cells/100 μL) cultured with supernatant obtained from hAM-MSCs (100 μL) cultured for 3 days. Data are expressed 
as the mean ± SE of four independent experiments. *p < 0.05, **p < 0.01.
Fig. 3. Cytokine levels in supernatant of co-cultured hAM-MSCs and PBMCs stimulated with mitogen. PBMCs (1 × 10
6 cells) cultured
with ConA (5 μg/mL) in the presence or absence of hAM-MSCs (1 × 10
5 cells) for 3 days. Production of TGF-β (A), IL-10 (B), IL-17
(C), and interferon-gamma (IFN-γ; D) was assessed in 3-day culture supernatant using a sandwich ELISA kit. Data are expressed as the
mean ± SE of five independent experiments. ND: not detected, *p < 0.05, **p < 0.01.28    Jung Won Kang et al.
Fig. 4. Induction of immunomodulatory factor production in hAM-MSCs by co-culturing with PBMCs. hAM-MSCs (1 × 10
5 cells) 
cultured with or without PBMCs (1 × 10
6 cells) in the presence of ConA (5 μg/mL) for 12 h or 3 days. (A) mRNA expression of COX-2,
TGF-β, HGF, and IDO in AM-MSCs cultured with or without PBMCs for 12 h was evaluated by RT-PCR. GAPDH was used as an 
internal control. (B) IDO enzymatic activity was indirectly determined spectrophotometrically by measuring the amount of kynurenine
in 3-day culture supernatant from hAM-MSCs/PBMCs co-cultures. (C) The level of prostaglandin E2 in the supernatant from 
co-cultured hAM-MSCs and PBMCs was determined by sandwich ELISA. **p < 0.01.
immune cells, we measured the production of IL-17, 
IFN-γ, TGF-β, and IL-10 in culture supernatant obtained 
from a co-culture of hAM-MSCs (1 × 10
5) and PBMCs (1 
× 10
6). As shown in Fig. 3, lower levels of IL-17 and IFN-γ 
production were observed in the supernatant from 
co-cultures of hAM-MSCs and PBMCs in the presence of
mitogens compared to the supernatant obtained from 
cultures of PBMCs alone (p < 0.05). However, the level of 
IL-10 and TGF-β production increased significantly in the 
supernatant obtained from the co-cultures of hAM-MSCs 
and PBMCs (p < 0.01).
Increased expression of immunomodulatory factors 
in hAM-MSCs co-cultured with allogeneic PBMCs
Among all molecules we evaluated, mRNA expression of 
TGF-β, HGF, IDO, and COX-2 was induced more, not 
only in hAM-MSCs grown in the presence of PBMCs but 
also in hAM-MSCs separated from PBMCs by transwells 
compared to those grown without PBMCs (Fig. 4A). PGE2 
and IDO are known key factors of immune tolerance as 
well as immune modulators of MSCs. Therefore, we 
measured PGE2 and kynurenine levels in the supernatant 
obtained from hAM-MSC/PBMC co-cultures. As shown 
in Figs. 4B and C, higher levels of kynurenine production 
and PEG2 were observed in the supernatant obtained from 
the co-culture.
Discussion
MSCs have received attention for their differentiation 
ability and therapeutic potential in regenerative medicine. 
Although the mechanism underlying the immune-modulation 
of MSCs remains to be elucidated, it is now clear that these 
cells can suppress allogeneic immune responses. Several 
studies have recently shown that amniotic membrane-derived 
cells display immunomodulatory properties similar to Immune-modulation by hAM-MSC    29
those described for MSCs obtained from other sources 
such as bone marrow and adipose tissue [4,15]. Similar to 
other MSCs, the mechanism of immune-modulation by 
hAM-MSCs is yet to be clarified. In the present study, we 
demonstrated the following: (1) hAM-MSCs inhibited 
mitogen-induced proliferation of allogeneic PBMCs; (2) 
these effects were caused by not only contact with 
hAM-MSCs but also MSC culture supernatant; (3) hAM- 
MSCs caused PBMCs to secrete anti-inflammatory cyto-
kines, especially IL-10; and (4) hAM-MSCs produced 
IDO, PGE2, TGF-β, and HGF, factors that might induce 
suppression of proliferation and inflammatory cytokines 
production of immune cells. These data indicate that those 
suppressive effects on proliferation and inflammatory 
cytokines production of immune cells by hAM-MSCs 
might be partially mediated by soluble factors, which is 
consistent with findings from other types of MSCs [1,13].
IL-10 is a well-known cytokine involved in cell regulation 
and promotion of proliferation and activation of regulatory 
or anti-inflammatory cells. Previous studies have been 
performed that show increases in IL-10 production in a 
mixed lymphocyte population co-cultured with hBM- 
MSCs [1,3,11,12] and in plasmacytoid dendritic cells 
(DCs) co-cultured with BM-MSCs and human adipose 
tissue-derived MSCs (hAD-MSCs) [27]. On the other 
hand, other groups found no change in IL-10 production 
when hBM-MSCs and PBMCs were co-cultured and 
stimulated with phytohaemagglutinin [21], or IL-10 did 
not detected when hAD-MSCs and PBMCs were co- 
cultured [20]. Our data showed increased levels of IL-10 in 
supernatant from co-cultures of hAM-MSCs and PBMCs. 
hAM-MSCs did not produce IL-10. Rather, IL-10 was 
secreted from PBMCs, indicating that T cells or antigen 
presenting cells might be influenced by a paracrine effect. 
Soluble factors from mouse BM-MSCs induce IL-10 
production by mouse splenocytes, which in turn suppress 
the proliferation of T cells by inducing apoptosis [25]. 
Furthermore, production of HLA-G, a known immuno-
modulatory factor, is induced via IL-10 [17]. However, 
there are no previous studies that investigated induction of 
IL-10 production by hAM-MSCs. Thus, further investiga-
tions are needed to verify the effects of IL-10 induced by 
hAM-MSCs on immune cells and the mechanism of 
induced IL-10 production by hAM-MSCs.
According to previous reports, anti-TGF-β antibody 
abrogates immune suppression by MSCs and recombinant 
TGF-β enhances the immunomodulatory properties of 
MSCs [7,23]. However, Le Blanc et al. [13] and Tse et al. 
[25] reported no significant restoration in T-cell prolife-
ration as a result of treatment with anti-TGF-β antibody. 
We observed increased expression of TGF-β mRNA in 
hAM-MSCs 12 h after co-culturing with leukocytes and 
the constitutive expression of TGF-β m RN A  in  h A M-  
MSCs. Furthermore, we observed an increased level of 
TGF-β in the culture supernatant obtained from hAM- 
MSCs and PBMCs co-cultured for 3 days, indicating that 
TGF-β secreted by hAM-MSCs may participate in the 
immunomodulatory effect on PBMCs.
IDO, a well-known immune-suppression factor not 
expressed constitutively in MSCs, inhibits T-cell prolife-
ration and promotes immune tolerance by tryptophan 
depletion [16]. Although Tse et al. [25] reported that IDO 
inhibitors do not restore T-cell proliferation, other studies 
showed that IDO production  in hBM-MSCs are induced 
by IFN-γ produced by T cells. Moreover, hBM-MSCs 
induce T-cell apoptosis via IDO [18] and T-cell prolife-
ration is restored by IDO inhibitors [12]. In our study, IDO 
mRNA was not constitutively expressed in hAM-MSCs. 
However, IDO mRNA and kynurenine production 
increased when hAM-MSCs and PBMCs were co- 
cultured, suggesting that IDO was induced by co-culturing 
and participated in immune modulation by hAM-MSCs. 
PGE2, one of the MSC immune-modulation candidates, 
that is synthesized from arachidonic acid by COX-1 and 
COX-2 enzymes regulates the maturation and antigen 
presentation of DC, and inhibits T cell proliferation and 
cytokine production [26]. MSCs constitutively express the 
COX enzymes, indicating that PGE2 is also constitutively 
expressed. According to Aggarwal et al. [1], the PGE 
production pattern is bell-shaped and occurs in a 
time-dependent manner, indicating that this factor might 
be related to early immune suppression by MSCs. Our 
results also showed that COX-2 mRNA and PEG2 
production increased in hAM-MSCs when they were 
co-cultured with PBMCs. A previous study showed that 
PGE2 and TGF-β from BM-MSCs induce the proliferation 
of CD4
+ CD25
high FOXP
3+ regulatory T cells [8].These 
induced Treg cells suppressed allogeneic immune 
responses, indicating that soluble factors from MSCs do 
not solely suppress immune responses [8]. Moreover, 
blocking PGE2 production in the T cells/hAD-MSCs 
co-culture resulted in a significant decrease of IL-10 
production [26]. PGE2 is the most powerful immuno-
modulatory factor in human umbilical cord-derived MSCs 
(hUC-MSCs). This is because inhibition of PGE synthesis 
almost completely mitigates the immunosuppressive 
effects whereas neutralization of TGF-β and IDO has little 
effect [5]. Thus, further studies are necessary to determine 
whether hAM-MSCs induce the proliferation of Treg cells 
via PGE2 and TGF-β.
Supernatants from hAM-MSCs had a partial inhibitory 
effect on PBMC proliferation suggesting that presence of 
soluble factors in the supernatant might have inhibited 
PBMCs proliferation. Thus, further studies on the sufficient 
induction of soluble factors from hAM-MSCs by pre- 
treatment with inducers or genetic engineering may be 
needed before these hAM-MSCs can be used for clinical 
purposes. Although we found that soluble factors inhibited 30    Jung Won Kang et al.
the proliferation and inflammatory cytokines production 
of immune cells, cell-cell contact between MSCs and 
lymphocytes is also one of the possible mechanisms 
underlying the immuno-modulatory effects of MSCs. 
Cell-cell contact between BM-MSCs and lymphocytes 
induced IL-10 and TGF-β transcription in BM-MSCs. 
Moreover, cell adhesion molecules, such as B7-H1, 
intercellular adhesion molecule-1 (ICAM-1) and vascular 
cell adhesion molecule-1 (VCAM-1), may participate in 
immune-modulation. Immune-modulation by hUC-MSCs 
is largely mediated by cell-cell contact via  adhesion 
molecules, particularly B7-H1 [24]. Moreover, the adhesion 
molecules ICAM-1 and VCAM-1 mediated immuno-
suppression in mouse BM-MSCs induced by IFN-γ from 
activated T cells; this activity was abrogated by antibodies 
against ICAM-1 and VCAM-1 [22]. Thus, cell-cell contact 
between hAD-MSCs and PBMCs may play an important 
role in the immunomodulatory effects of hAD-MSCs. 
Further studies examining the effects of cell-cell contact on 
the immunomodulatory properties of hAD-MSCs are 
necessary.
There are some differences in immune-modulation 
mechanisms among human MSCs from various sources. 
These differences could be explained by methodological 
differences such as the co-culture time, ratio of MSCs and 
immune cell in the co-culture, or source of the MSCs. 
Therefore, further studies should be performed to measure 
the effect of these differences on the immune-modulation 
effects of MSCs and establish a standardization system for 
these various methods. In conclusion, we found that 
soluble factors produced by hAM-MSCs might suppress 
allogeneic immune responses via induction of IL-10 
production, supporting the hypothesis that these cells have 
potential therapeutic use. Further study is needed to 
identify the detailed mechanisms responsible for the 
immunomodulatory effects of hAM-MSCs.
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